| Name | Title | Contact Details |
|---|---|---|
Kashif Hasan |
Director, Key Customer Marketing | Profile |
Carolyn Schwarz |
Associate Director, Field Sales Strategy | Profile |
Samantha Ortiz |
Director, HR Business Partner | Profile |
Alejandro Castro |
Director Gross to Net Finance | Profile |
Jean Miaw |
Senior Director, Revenue Forecasting | Profile |
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
SOL (CSE:SOL) is an international cannabis company with a focus on legal U.S. states. Its strategic investments and partnerships across cultivation, distribution and retail complement the company`s R&D program with the University of Miami.
IsoPlexis is leading a new era of functional proteomics. By identifying our most proteomically active single cells (or "superhero cells") for the first time, IsoPlexis enables researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at the majority of leading U.S. comprehensive cancer centers.
The Protein Data Bank (PDB) was established as the 1st open access digital data resource in all of biology and medicine. It is today a leading global resource for experimental data central to scientific discovery.
4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR).